Changing the paradigm of treating neurodegenerative disease
Our mission is to translate unique genetic and biochemical insights regarding lipid biology into therapies that promote brain health and repair. We believe our novel technology platform and approach will unlock new opportunities to address significant unmet need across a range of acute and chronic conditions, including Traumatic Brain Injury, Stroke, Multiple Sclerosis, and Alzheimer’s Disease.
Great teams are required to achieve great success
We are a growing team of scientists and entrepreneurs dedicated to advancing our technology in service of patients and their loved ones. With a diverse culture of experience and perspective, we strive to support and challenge one another, fostering an environment of care, respect, and collaboration. New ideas and innovation fuel us. Science and data guide us. Novel challenges and opportunities bring out our best. Passionate and driven, we aspire to overcome obstacles with creativity and careful risk-taking, knowing that we are making a difference in the lives of patients.
At Kisbee, we believe that great teams are built on a foundation of kindness, honesty, and balance. We work hard, but recognize that we all have lives outside the lab and office. We celebrate our successes as much as our failures, knowing that both are stepping stones on the journey to changing the way we approach brain health. Together, we will redefine the way we treat neurodegenerative disease.
Meet the experts behind our vision
Kisbee is an exciting fast-growing company with tremendous career growth opportunity. We are actively hiring across a range of roles in R&D, HR, Finance, and Operations. To inquire about open roles, please email recruiting@kisbeetx.com
Stuart L. Schreiber, Ph.D. is co-Founder of the Broad Institute, Howard Hughes Medical Institute Investigator, Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University, and has been a member of the National Academy of Sciences since 1995. His research has been recognized through numerous awards, most recently the Wolf Prize in Chemistry.
Dr. Schreiber’s research integrates chemical biology and human biology to advance the discovery of novel therapeutics. He is known for his use of small molecules to explore biology and medicine, and for his role in the development of the field of chemical biology. His lab discovered mTOR and illuminated the nutrient-response signaling network, histone deacetylase (HDAC) and the role of chromatin marks in gene expression, and with Gerry Crabtree mapped the first membrane to nuclease signaling pathway (calcium–calcineurin–NFAT). His work demonstrated for the first time that drugs can result from: 1) the targeting of protein kinases (sirolimus/mTOR) and protein phosphatases (sandimmune/calcineurin); 2) gene regulation by chromatin-modifying enzymes (vorinostat/HDAC), 3) small-molecule dimerizers that activate cellular processes by enforced proximity (GVH Disease), and 4) targeting of the proteasome (bortezomib/proteasome). These efforts accelerated the development of many additional widely used drugs.
Dr. Schreiber extended chemical biology principles to medicine by founding several biotech companies, including Vertex Pharmaceuticals (fosamprenavir/Lexiva; telaprevir/Incivek; ivacaftor/Kalydeco), ARIAD Pharmaceuticals (ponatinib/Iclusig; brigatinib/Alunbrig; ridaforolimus; AP1903), Infinity Pharmaceuticals (reta¬spimycin; duvelisib), Forma Therapeutics, H3 Biomedicine and Jnana Therapeutics.
